Widespread cutaneous reaction to the Johnson & Johnson Ad26.COV2.S vaccine

Affiliations

¹ University of Alabama at Birmingham, Birmingham, Alabama.
² Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama.

Josiah Sowell et al. JAAD Case Rep. 2022 Apr.

. 2022 Apr:22:56-57.

doi: 10.1016/j.jdcr.2021.08.037. Epub 2021 Nov 3.

¹ University of Alabama at Birmingham, Birmingham, Alabama.
² Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama.

No abstract available

Keywords: Ad26.COV2.S; COVID-19; Johnson & Johnson; cutaneous reaction; delayed hypersensitivity; diffuse eruption; vaccine.

Conflict of interest statement

None disclosed.

1. Lospinoso K., Nichols C.S., Malachowski S.J., Mochel M.C., Nutan F. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep. 2021;13:134–137. doi: 10.1016/j.jdcr.2021.05.010. - DOI - PMC - PubMed
1. Centers for Disease Control and Prevention Johnson & Johnson's Janssen COVID-19 vaccine overview and safety. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/ja...
1. Livingston E.H., Malani P.N., Creech C.B. The Johnson & Johnson vaccine for COVID-19. JAMA. 2021;325(15):1575. doi: 10.1001/jama.2021.2927. - DOI - PubMed
1. United States Food and Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021. FDA Briefing Document Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. https://www.fda.gov/media/146217/download
1. CDC COVID-19 Response Team, Food and Drug Administration Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125–129. doi: 10.15585/mmwr.mm7004e1. - DOI - PMC - PubMed